Daily FNArena News

Nomura has initiated coverage on Prima Biomed with a Buy rating, attracted to the group’s potential to develop an immunotherapy-based treatment for ovarian cancer.

Softening Chinese steel demand suggests a weak short-term outlook for steel but expectations remain for a tighter market and higher margins from 2013.

The Conference Board believes average global GDP growth will slow into at least next decade, while a PIMCO survey finds an increasing number of global pessimists, with Australians among them.

Forex.com’s Kathleen Brooks asks the obvious question now that financial markets are back in turmoil.

Despite a more influential domestic economy, China will still be impacted by loss of export demand in the wake of the European crisis.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. RBS analysts still see entry opportunity ahead of the earnings surge for mining services companies from FY13.

Paolo Manasse, professor of macroeconomics and international economic policy at the University of Bologna, argues Berlusconi’s departure is necessary but not sufficient to address Italy’s debt issues.

A glance through the latest expert views and predictions about commodities, with cost curves expected to support prices, an over-reaction in iron ore prices and adjustments to metal price estimates.

The Chartist remains cautiously optimistic on the outlook for the Australian share market.

Your Editor appeared on Switzer TV to explain the difference between “good weather stocks” and stocks investors should own in long term portfolios.